Skip to main content
Premium Trial:

Request an Annual Quote

GenapSys to Offer Twist Bioscience Library Prep, Target Enrichment Products

NEW YORK — GenapSys said on Monday that it has signed an agreement to offer Twist Bioscience's library preparation and target enrichment products to customers of its portable DNA sequencing system.

GenapSys launched its lunchbox-sized electronic sequencer, which uses microfluidic CMOS chips and has a list price of $10,000, in late 2019.

Under the terms of the deal, Redwood City, California-based GenapSys will begin integrating the Twist products into its portfolio in the second quarter. Additional terms were not disclosed.

"This OEM collaboration with GenapSys provides an ideal option for research laboratories, government organizations and sequencing providers, including healthcare facilities, to get access to our assays on GenapSys distributed sequencers," Emily Leproust, cofounder and CEO of San Francisco-based Twist, said in a statement. "With the distributed nature of the GenapSys high accuracy and affordable sequencer, there is the potential for wider adoption [of our products], benefitting a greater number of researchers and clinicians."

Earlier this month, GenapSys raised up to $75 million in debt financing and inked deals with more than 25 distributors worldwide. Twist, meanwhile, recently priced a $130 million public offering of common stock, which it expects to close today.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.